Review papers with raw data transparency

• Problem: Early detection limitations mean many patients are not surgical candidates; improved precision diagnostics are needed. Early detection and surgical candidacy motivation
• Core hypothesis: Liquid biopsy biomarkers (CTCs, circulating tumor cells derivatives, circulating miRNAs, extracellular vesicles) could support diagnosis, prognosis, and treatment monitoring depending on analyte-specific sensitivity/specificity. Liquid biopsy scope
• Clinical staging role: The review frames liquid biopsy as enabling non-invasive, longitudinal molecular readouts for molecular stratification and therapy response prediction/monitoring. Longitudinal non-invasive molecular monitoring

3.1 What we can infer vs what we cannot

• Known (from the paper): The authors position liquid biopsy as a promising non-invasive strategy for early diagnosis, prognosis, and monitoring, but also emphasize that translational hurdles exist. Promise + need for validation
• Uncertain: The review frequently summarizes study-level performance (e.g., sensitivity/specificity/AUC) but, as a narrative review, it does not provide a unified meta-analytic framework in the provided text, so you should treat comparative performance across biomarkers as context-dependent and not directly rankable without method-standardized head-to-head studies. Comparability/validation limitations noted in conclusions
• Not supported in the review methodology: The paper explicitly states that no datasets were generated/analysed by the authors, consistent with a review rather than primary experimental work. No new datasets generated

3.2 Red flags & likely sources of bias

• Narrative review risk: Narrative synthesis can be susceptible to selection bias and inconsistent inclusion criteria across subtopics (even if individual cited studies are rigorous). The manuscript’s scope is broad (CTCs, ctDNA, miRNAs, EVs), increasing the likelihood of uneven evidence density. Review nature and broad scope
• Small study problem: The paper’s conclusions explicitly state that many studies are generally small and lack statistical power for firm conclusions about associated clinical parameters. Small study / power limitation
• Assay standardization & threshold instability: The review highlights that different detection techniques produce debate around optimal thresholds, and that EV isolation/purification lacks standardized protocols with low yield/purity using common methods. Standardization and threshold challenges
• Specificity in cirrhosis/inflammation context: Because cfDNA/miRNA/EV signals can arise from non-tumor processes, clinical discrimination must be tested against relevant liver disease controls; the paper notes false-positive/diagnostic specificity challenges indirectly via emphasis on rigorous validation and biomarker panels. Diagnostic specificity depends on analyte & validation

• Strongest support: The review consistently argues that liquid biopsy is biologically plausible and operationally attractive for longitudinal monitoring, and it clearly identifies translational bottlenecks (assay standardization, thresholds, and the need for adequately powered prospective validation). Promise + translational bottlenecks
• Key limitation of the review itself: Because it is a review and no new datasets are analyzed, it cannot resolve conflicting or heterogeneous results; the field needs harmonized study designs and auditable evaluation metrics. No new data + need for validation
• Confidence: High confidence in the direction (liquid biopsy is promising but requires validation); lower confidence in any ranking of specific biomarkers without meta-analytic standardization or head-to-head trials. Comparative uncertainty